Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
Investigational New Drugs
|
December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Frontiers in Oncology
|
July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Clinical Colorectal Cancer
|
April 23, 2024
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
Eric X Chen, Petr Kavan, Mustapha Tehfe, et al.
Frontiers in Oncology
|
April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Sarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget
|
October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
Christopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
The American Journal of Gastroenterology
|
May 13, 2021
The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry
Samuel Han, Jennifer M Kolb, Patrick Hosokawa, et al.
Cancers
|
August 29, 2024
Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors
Salvador Rodriguez Franco, Sumaya Abdul Ghaffar, Ying Jin, et al.
Cancer Research Communications
|
September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment
Jesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer
|
October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
S Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
Investigational New Drugs
|
December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Frontiers in Oncology
|
July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Clinical Colorectal Cancer
|
April 23, 2024
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
Eric X Chen, Petr Kavan, Mustapha Tehfe, et al.
Frontiers in Oncology
|
April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Sarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Oncotarget
|
October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
Christopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
The American Journal of Gastroenterology
|
May 13, 2021
The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry
Samuel Han, Jennifer M Kolb, Patrick Hosokawa, et al.
Cancers
|
August 29, 2024
Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors
Salvador Rodriguez Franco, Sumaya Abdul Ghaffar, Ying Jin, et al.
Cancer Research Communications
|
September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment
Jesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer
|
October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
S Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Page
of 7